In its news of November 21, the National Agency for the Safety of Medicines and Health Products (ANSM) announces that it is recalling a batch of generic atorvastatin Arrow 10 mg vials, a cholesterol treatment. In question, the discovery of a type 2 diabetes treatment tablet in a bottle.
The ANSM explains that it was informed by the Arrow laboratory of a packaging error in one of the treatments. Indeed, they noted the presence of a Gliclazide 30 mg modified release tablet (hypoglycemic), this is a medication usually used against diabetes. At this time, this packaging error has only been reported for one vial. In addition, this recall does not affect boxes of atorvastatin in blister packs.
Also, people in possession of a vial of generic atorvastatin Arrow 10 mg from lot JBM2300810F “are invited to return it to the pharmacy so that it can be replaced”. As a reminder, atorvastatin 10 mg is a medication used in the long-term treatment of cholesterol. The ANSM specifies that “the laboratory does not identify any risk of supply tension linked to this recall”.
As the ANSM specifies, “the two tablets are white in color, but their shape and engraving are different”. Although, for the moment, no cases have been reported, an error in taking this treatment can cause hypoglycemia, i.e. blood sugar levels that are too low. It manifests itself in particular (…)
(…) Click here to see more
